Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alonso-Dominguez Juan M, Castaño-Bonilla Tamara, Gil Cristina, Serrano-Lopez Josefina, Martinez-Sanchez Pilar, Herrera Pilar, Garcia-Boyero Raimundo, Rodriguez-Arboli Eduardo, Brioso-Infante Joana, Benavente Celina, Lavilla-Rubira Esperanza, Tormo Mar, Sayas-Lloris Maria J, Lainez-Gonzalez Daniel, Serrano-Lopez Juana, Amigo Maria L, Algarra Lorenzo, Unamunzaga Ariane, Alonso-Alonso Jose M, Garcia-Garay Maria C, Callejas-Charavia Marta, Roldan-Perez Alicia, Cornago-Navascues Javier, Valero-Nuñez Marta, Alfonso-Pierola Ana, Perez-Santaolalla Esther, Sobas Marta, Romero-Riquelme Monica, Lopez Miguel, Galvez Kenny, Rodríguez-Veiga Rebeca, Barragan Eva, Ayala Rosa, Solana-Altabella Antonio, Lloret-Madrid Pilar, Montesinos Pau
Аннотация
METHODS: In this study, the authors interrogated Programa Español de Tratamientos en Hematología (PETHEMA) AML epidemiologic registry to shed light on the outcome of patients with AML harboring BCR::ABL1.
RESULTS: Fifty-seven patients with newly diagnosed AML harboring BCR::ABL1 were included, 40 of them treated intensively. Fifteen patients received TKI and 19 did not receive TKI, median overall survival (mOS) was 15.7 months (95% CI, 3.9-27.6 months) and 12.3 months (95% CI, 0.4-24.1 months), respectively (p = .28). Median relapse-free survival was not reached versus 7.6 months (95% CI, 3-12.2 months) in patients who did or did not receive TKI (p = .029). Age, TKI treatment, allogeneic bone marrow transplantation and date of diagnosis were included in the Cox regression analysis, and no independent prognostic factors for OS were found. Comparison of BCR::ABL1 AML patients with the intensively treated global PETHEMA AML cohort (N = 2107) showed that patients who received a TKI had a median overall survival similar to that of the intermediate‑risk group.
CONCLUSIONS: This study shows improved outcomes with the addition of TKI to chemotherapy and supports re-classification of AML patients harboring BCR::ABL1 in the intermediate-risk group. Nonetheless, given the small sample size, larger studies are needed to confirm these findings.